ArticleFrontiers in neurology2023
The Acute Optic Neuritis Network (ACON): Study protocol of a non-interventional prospective multicenter study on diagnosis and treatment of acute optic neuritis.
Registry-linked trialAbstract read
In one paragraph
Article in Frontiers in neurology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05605951 (The Acute Optic Neuritis Network), which is not on this map. Cited by 9 papers.
0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
The Acute Optic Neuritis Network (ACON): a Non-interventional Prospective Multicenter Study on Diagnosis and Treatment of Acute Optic Neuritis
Who cites it
9 citing papers in PubMed.
- Disease Course of Clinically Isolated Optic Neuritis.Neurology(R) neuroimmunology & neuroinflammation · 2024Trial
- Significant Visual Field Defects Persist Despite Excellent Visual Acuity Following Optic Neuritis in Myelin-Oligodendrocyte Glycoprotein Associated Disease.Neuro-ophthalmology (Aeolus Press) · 2026Article
- Treatment of optic neuritis with erythropoietin: impact on white matter and optic nerve MRI characteristics.Brain communications · 2026Article
- Serum Neurofilament Light Is Associated With Future Disease Activity in Clinically Isolated Syndrome and Early Multiple Sclerosis Only After Non-Optic Neuritis Onset.European journal of neurology · 2025Article
- New optical coherence tomography biomarker for diagnosis of acute optic neuritis in multiple sclerosis.Heliyon · 2025Article
- Retinal Damage and Visual Network Reconfiguration Defines Visual Function Recovery in Optic Neuritis.Neurology(R) neuroimmunology & neuroinflammation · 2024Article
- Application of the international criteria for optic neuritis in the Acute Optic Neuritis Network.Annals of clinical and translational neurology · 2024Observational
- Effectiveness of oral prednisone tapering following intravenous methylprednisolone for acute optic neuritis in multiple sclerosis.PloS one · 2023Article
- Development of a predictive model for predicting disability after optic neuritis: a secondary analysis of the Optic Neuritis Treatment Trial.Frontiers in neurology · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
62 authors.
Susanna AsseyerExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Nasrin AsgariDepartment of Neurology, Slagelse Hospital, Slagelse, Denmark.
Jeffrey BennettPrograms in Neuroscience and Immunology, Departments of Neurology and Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Omer BialerDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Yolanda BlancoNeuroimmunology and Multiple Sclerosis Unit, Neurology Service, Hospital Clinic de Barcelona, and Institut d'Investigacions August Pi i Sunyer (IDIVAPS), University of Barcelona, Barcelona, Spain.
Francesca BoselloNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
Anna Camos-CarrerasOphthalmology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Edgar Carnero ContenttiNeuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
Sara CartaNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
John ChenDepartment of Ophthalmology and Neurology, Mayo Clinic, Rochester, MN, United States.
Claudia ChienExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Mashina ChombaDepartment of Internal Medicine, University Teaching Hospital, Lusaka, Zambia.
Russell C DaleClinical Neuroimmunology Group, Kids Neuroscience Centre, Sydney, NSW, Australia.
Josep DalmauICREA-IDIBAPS, Service of Neurology, Hospital Clínic, University of Barcelona, Barcelona, Spain.
Kristina FeldmannExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Eoin P FlanaganLaboratory Medicine and Pathology, Departments of Neurology, Center for MS and Autoimmune Neurology, Mayo Clinic, Rochester, MN, United States.
Caroline Froment TiliketeNeuro-Ophthalmology Unit, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon 1 University, Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, IMPACT Team, Lyon, France.
Carolina Garcia-AlfonsoPontificia Universidad Javeriana and Hospital Unviersitario San Ignacio, Bogotá, Colombia.
Joachim HavlaInstitute of Clinical Neuroimmunology, LMU Hospital, Ludwig-Maximilians-Universität München, Munich, Germany.
Mark HellmannDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Ho Jin KimDepartment of Neurology, National Cancer Center, Goyang, Republic of Korea.
Philipp KlysczExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Frank KonietschkeCharité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Experimental and Clinical Research Center, Berlin, Germany.
Chiara La MorgiaNeurology Unit, IRCCS Institute of Neurological Sciences, Bologna, Italy.
Marco Lana-PeixotoCIEM MS Center, Federal University of Minas Gerais Medical School, Belo Horizonte, Brazil.
Maria Isabel LeiteDepartment of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, United Kingdom.
Netta LevinDepartment of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Michael LevyNeuromyelitis Optica Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Sara LlufriuNeuroimmunology and Multiple Sclerosis Unit, Neurology Service, Hospital Clinic de Barcelona, Barcelona, Spain.
Pablo LopezNeuroimmunology Unit, Department of Neuroscience, Hospital Aleman, Buenos Aires, Argentina.
Itay LotanDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Alessandra LugaresiIRCCS Istituto delle Scienze Neurologiche di Bologna, Bologna, Italy.
Romain MarignierNeuro-Ophthalmology Unit, Pierre Wertheimer Neurological Hospital, Hospices Civils de Lyon, Lyon 1 University, Lyon Neuroscience Research Center, INSERM U1028, CNRS UMR5292, IMPACT Team, Lyon, France.
Sara MariottoNeurology Unit, Department of Neurosciences, Biomedicine, and Movement Sciences, University of Verona, Verona, Italy.
Susan P MollanBirmingham Neuro-Ophthalmology, Queen Elizabeth Hospital, University Hospitals Birmingham NHS Foundation Trust, Birmingham, United Kingdom.
Cassandra OcampoFaculty of Medicine, University of Botswana, Gaborone, Botswana.
Frederike Cosima OertelExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Maja OlszewskaNeuroCure Clinical Research Center, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany.
Jacqueline PalaceDepartment of Neurology, Oxford University Hospitals, National Health Service Trust, Oxford, United Kingdom.
Lekha PanditCenter for Advanced Neurological Research, KS Hegde Medical Academy, Nitte (Deemed to be University), Mangalore, India.
José Luis Peralta UribePontificia Universidad Javeriana and Hospital Unviersitario San Ignacio, Bogotá, Colombia.
Sean PittockNeuromyelitis Optica Research Laboratory, Massachusetts General Hospital and Harvard Medical School, Boston, MA, United States.
Sudarshini RamanathanFaculty of Medicine and Health and Brain and Mind Centre, University of Sydney, Sydney, NSW, Australia.
Natthapon RattanathamsakulSiriraj Neuroimmunology Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Albert SaizNeuroimmunology and Multiple Sclerosis Unit, Neurology Service, Hospital Clinic de Barcelona, Barcelona, Spain.
Sara SamadzadehExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Bernardo Sanchez-DalmauOphthalmology Department, Hospital Clínic de Barcelona, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain.
Deanna SaylorDepartment of Internal Medicine, University Teaching Hospital, Lusaka, Zambia.
Michael ScheelExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Tanja Schmitz-HübschExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Jemal ShifaDepartment of Surgery, University of Botswana, Gaborone, Botswana.
Sasitorn SirithoSiriraj Neuroimmunology Center, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, Thailand.
Pia S SperberExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Prem S SubramanianPrograms in Neuroscience and Immunology, Departments of Neurology and Ophthalmology, Sue Anschutz-Rodgers Eye Center, University of Colorado Anschutz Medical Campus, Aurora, CO, United States.
Alon TiosanoDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Adi Vaknin-DembinskyDepartment of Neurology, Hadassah Medical Center, Hebrew University, Jerusalem, Israel.
Alvaro Jose Mejia VergaraDepartment of Ophthalmology, Fundación Universitaria Sanitas Facultad de Medicina, Bogotá, Colombia.
Adi Wilf-YarkoniDepartment of Neurology, Sackler Faculty of Medicine, Tel-Aviv University, Tel-Aviv, Israel.
Luis Alfonso ZarcoPontificia Universidad Javeriana and Hospital Unviersitario San Ignacio, Bogotá, Colombia.
Hanna G ZimmermannExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Friedemann PaulExperimental and Clinical Research Center, A Cooperation Between the Max Delbrück Center for Molecular Medicine in the Helmholtz Association and Charité Universitätsmedizin Berlin, Berlin, Germany.
Hadas Stiebel-KalishDepartment of Neuro-Ophthalmology, Rabin Medical Center, Petah Tikva, Israel.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Optic neuritis (ON) often occurs at the presentation of multiple sclerosis (MS), neuromyelitis optica spectrum disorders (NMOSD), and myelin oligodendrocyte glycoprotein (MOG) antibody-associated disease (MOGAD). The recommended treatment of high-dose corticosteroids for ON is based on a North American study population, which did not address treatment timing or antibody serostatus. The Acute Optic Neuritis Network (ACON) presents a global, prospective, observational study protocol primarily designed to investigate the effect of time to high-dose corticosteroid treatment on 6-month visual outcomes in ON. Patients presenting within 30 days of the inaugural ON will be enrolled. For the primary analysis, patients will subsequently be assigned into the MS-ON group, the aquapotin-4-IgG positive ON (AQP4-IgG+ON) group or the MOG-IgG positive ON (MOG-IgG+ON) group and then further sub-stratified according to the number of days from the onset of visual loss to high-dose corticosteroids ( Trial registration: ClinicalTrials.gov, identifier: NCT05605951.
Indexed as
Aquaporin-4-IgG (AQP4-IgG)clinically isolated syndrome (CIS)MOG-IgG associated disorders (MOGAD)multiple sclerosis (MS)neuromyelitis optica spectrum disorders (NMOSD)optic neuritis (ON)
Identifiers
What OpenQuestion holds
Textmetadata
LicenceCC BY
Read underepoch 390
Registered trials
NCT05605951ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.